BioSpace News Archive

Central Virginia VA Health Care System Recognized for Innovation and Care Delivery Excellence in the Care of Fatty Liver Disease [09-January-2020] NEW YORK , Jan. 9, 2020 /PRNewswire/ -- Eight leading care delivery systems from across the country have been designated as founding charter members of NASHNET and Centers of Excellence (COEs). In partnership with The Kinet

First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020

Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing Platform

Co-Diagnostics, Inc. announced that it has been recognized as a company that represents the Nasdaq Biotech Index in leading the nation in solving America’s Healthcare challenges following a year of several Company milestones, and invited to ring the Nasdaq Stock Market opening bell on January 13 in San Francisco, California.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it has identified a new group of patients with high levels of clinical benefit in response to its novel immunotherapy, and its combinations.

Eagle Pharmaceuticals, Inc. announced that the Company has resubmitted its New Drug Application for RYANODEX® for the treatment of exertional heat stroke, in addition to body cooling, to the U.S. Food and Drug Administration.

LHC Group, Inc. announced that the Company is presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020.

Bio-Techne Corporation announced that management will host a conference call on Tuesday, February 4, 2020, at 8:00 a.m. CST to review second quarter 2020 financial results.

MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval for the FRED® device for the treatment of brain aneurysms.

The investment arm of Debiopharm, a private, Swiss corporate fund specialized in Smart Data and Digital Health, leads the Series A